Standard BioTools (LAB) 10-Q 9 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	FLDM
Entity Registrant Name	FLUIDIGM CORP
Entity Central Index Key	1,162,194
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		28,897,109

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 42,854	$ 29,117
Short-term investments	52,365	65,855
Accounts receivable (net of allowances of $294 at March 31, 2016 and $103 at December 31, 2015)	19,643	25,457
Inventories	19,570	17,924
Prepaid expenses and other current assets	3,372	5,742
Total current assets	137,804	144,095
Long-term investments	0	6,493
Property and equipment, net	15,370	15,258
Other non-current assets	8,907	9,048
Developed technology, net	88,246	91,048
Goodwill	104,108	104,108
Total assets	354,435	370,050
Current liabilities:
Accounts payable	4,439	6,094
Accrued compensation and related benefits	5,420	3,553
Other accrued liabilities	11,560	11,015
Deferred revenue, current portion	9,101	9,419
Total current liabilities	30,520	30,081
Convertible notes, net	194,742	194,673
Deferred tax liability, net	22,496	23,595
Deferred revenue, net of current portion	5,256	4,398
Other non-current liabilities	2,444	2,402
Total liabilities	$ 255,458	$ 255,149
Commitments and contingencies (see Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000 shares authorized, no shares issued and outstanding at March 31, 2016 and December 31, 2015	$ 0	$ 0
Common stock, $0.001 par value, 200,000 shares authorized at March 31, 2016 and December 31, 2015; 28,896 and 28,844 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively	29	29
Additional paid-in capital	483,208	479,508
Accumulated other comprehensive loss	(885)	(1,144)
Accumulated deficit	(383,375)	(363,492)
Total stockholders’ equity	98,977	114,901
Total liabilities and stockholders’ equity	$ 354,435	$ 370,050

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 294	$ 103
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (shares)	10,000,000	10,000,000
Preferred stock, shares issued (shares)	0	0
Preferred stock, shares outstanding (shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (shares)	200,000,000	200,000,000
Common stock, shares issued (shares)	28,896,000	28,844,000
Common stock, shares outstanding (shares)	28,896,000	28,844,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue:
Product revenue	$ 25,370	$ 23,994
Service revenue	3,544	2,652
License and grant revenue	89	83
Total revenue	29,003	26,729
Costs and expenses:
Cost of product revenue	10,787	9,893
Cost of service revenue	1,198	753
Research and development	10,412	9,990
Selling, general and administrative	25,475	20,094
Total costs and expenses	47,872	40,730
Loss from operations	(18,869)	(14,001)
Interest expense	(1,453)	(1,453)
Other expense, net	(324)	(1,120)
Loss before income taxes	(20,646)	(16,574)
Benefit from income taxes	762	643
Net loss	$ (19,884)	$ (15,931)
Net loss per share, basic and diluted (in dollars per share)	$ (0.69)	$ (0.56)
Shares used in computing net loss per share, basic and diluted (shares)	28,863	28,468

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss Statement - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement of Comprehensive Income [Abstract]
Net loss	$ (19,884)	$ (15,931)
Other comprehensive (loss) income, net of tax
Unrealized gain on available-for-sale securities	81	55
Foreign currency translation adjustment	178	139
Other comprehensive loss, net of tax	259	194
Total comprehensive loss	$ (19,625)	$ (15,737)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating activities
Net loss	$ (19,884)	$ (15,931)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,565	1,338
Stock-based compensation expense	3,717	4,068
Amortization of developed technology	2,800	2,800
Other non-cash items	227	0
Changes in assets and liabilities:
Accounts receivable, net	5,532	3,096
Inventories	(1,822)	(1,321)
Prepaid expenses and other current assets	21	422
Other non-current assets	(127)	150
Accounts payable	(1,601)	(512)
Deferred revenue	505	1,294
Other current liabilities	2,332	(4,328)
Other non-current liabilities	(1,057)	(876)
Net cash used in operating activities	(7,792)	(9,800)
Investing activities
Purchases of investments	(8,514)	0
Proceeds from sales and maturities of investments	28,532	11,100
Proceeds from sale of investment in Verinata	2,330	0
Purchase of intangible assets	0	(120)
Purchases of property and equipment	(1,144)	(909)
Net cash provided by investing activities	21,204	10,071
Financing activities
Proceeds from exercise of stock options	5	3,732
Net cash provided by financing activities	5	3,732
Effect of foreign exchange rate fluctuations on cash and cash equivalents	320	(734)
Net increase in cash and cash equivalents	13,737	3,269
Cash and cash equivalents at beginning of period	29,117	33,713
Cash and cash equivalents at end of period	$ 42,854	$ 36,982

Description of Business

Description of Business	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Fluidigm Corporation (we, our, or us) was incorporated in the State of California in May 1999 to commercialize microfluidic technology initially developed at the California Institute of Technology. In July 2007, we were reincorporated in Delaware. Our headquarters are located in South San Francisco, California. We create, manufacture, and market innovative technologies and life-science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon our core microfluidics and mass cytometry technologies. We sell instruments and consumables, including integrated fluidic circuits (IFCs), assays, and reagents. Our customers include those both in research and applied markets. Research customers are predominantly academic institutions, while our applied customers include clinical laboratories, biopharmaceutical, agricultural biotechnology (Ag-Bio) companies, and contract research organizations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2015 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. These financial statements have been prepared on the same basis as our annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair statement of our financial information. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016 or for any other interim period or for any other future year. All intercompany accounts and transactions have been eliminated upon consolidation. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, income tax provisions, stock-based compensation, inventory valuation, allowances for doubtful accounts, and useful lives of long-lived assets. We base our estimates on historical experience and on various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the accompanying notes in Item 8 of Part II, "Financial Statements and Supplementary Data," for the year ended December 31, 2015 included in our Annual Report on Form 10-K. Prior Period Reclassifications Certain prior period amounts were reclassified to conform with the current period presentation under FASB Accounting Standards Update No. 2015-03 (ASU-2015-03), Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. As a result, we retroactively reclassified unamortized debt issuance costs of $1.0 million as of March 31, 2016 and December 31, 2015 from Other Non-Current Assets to a reduction of Convertible Notes, net on the condensed consolidated balance sheets. These reclassifications do not affect the condensed results of operations, retained earnings, or statement of cash flows in the current or previous interim reporting periods. Certain prior period amounts were reclassified to conform to the current period presentation of service revenue and cost of service revenue within our condensed consolidated statement of operations. These reclassifications do not affect total revenue, total costs and expenses, loss from operations, or net loss. Prior period amounts of revenue by geography have been reclassified to conform to the current period presentation to include license and grant revenue within our condensed consolidated statement of operations. The prior period amount of revenue by geography for revenue generated in Japan has been reclassified to conform to the current period presentation and included in revenue generated in Asia-Pacific. This reclassification does not affect total revenue, loss from operations, or net loss. Net Loss per Share Our basic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Restricted stock units and options to purchase common stock are considered to be potentially dilutive common shares but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented. The following potentially dilutive common shares were excluded from the computation of diluted net loss per share for the interim periods presented because they would have been anti-dilutive (in thousands): Three Months Ended March 31, 2016 2015 Stock options, restricted stock units and restricted stock awards 4,911 3,940 Convertible notes 3,598 3,598 Total 8,509 7,538 Accumulated Other Comprehensive Loss The components of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2016 are summarized as follows (in thousands): Net Unrealized Gain (Loss) on Marketable Securities Foreign Currency Translation Adjustment Accumulated Other Comprehensive Loss Balance at December 31, 2015 $ (72 ) $ (1,072 ) $ (1,144 ) Other comprehensive income 81 178 259 Balance at March 31, 2016 $ 9 $ (894 ) $ (885 ) Investment, at cost In February 2013, Illumina, Inc. acquired Verinata Health, Inc. (Verinata), a privately-held company, for $350 million in cash and up to an additional $100 million in milestone payments through December 2015. In March 2013, we received cash proceeds of $3.1 million in exchange for our ownership interest in Verinata resulting in a gain of $1.8 million . During the third quarter of 2014, we received cash proceeds of $0.3 million from the escrow account related to the acquisition. We recorded these amounts as "Gain from sale of investment in Verinata" in the consolidated statements of operations for the year ended December 31, 2014. The final milestones related to the sale of Verinata to Illumina were met in December 2015 and, accordingly, we recorded our share of these milestone payment obligations in the amount of $2.3 million in Gain from sale of investment in Verinata in the consolidated statement of operations for the year ended December 31, 2015. In January 2016, we received the payment of $2.3 million and it was recorded in net cash provided by investing activities in the condensed consolidated statement of cash flows. Business Combinations Assets acquired and liabilities assumed as part of a business acquisition are generally recorded at their fair value at the date of acquisition. The excess of purchase price over the fair value of assets acquired and liabilities assumed is recorded as goodwill. Determining fair value of identifiable assets, particularly intangibles, and liabilities acquired also requires management to make estimates, which are based on all available information, and in some cases, assumptions with respect to the timing and amount of future revenues and expenses associated with an asset. Accounting for business acquisitions requires management to make judgments as to whether a purchase transaction is a multiple element contract, meaning that it includes other transaction components such as a settlement of a preexisting relationship. This judgment and determination affects the amount of consideration paid that is allocable to assets and liabilities acquired in the business purchase transaction (See Note 4). Long-lived Assets, including Goodwill Goodwill and intangible assets with indefinite lives are not subject to amortization, but are tested for impairment on an annual basis during the fourth quarter or whenever events or changes in circumstances indicate the carrying amount of these assets may not be recoverable. We first conduct an assessment of qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we determine that it is more likely than not that the fair value of our reporting unit is less than its carrying amount, we then conduct a two-step test for impairment of goodwill. In the first step, we compare the fair value of our reporting unit to its carrying value. If the fair value of our reporting unit exceeds its carrying value, goodwill is not considered impaired and no further analysis is required. If the carrying value of the reporting unit exceeds its fair value, then the second step of the impairment test must be performed in order to determine the implied fair value of the goodwill. If the carrying value of the goodwill exceeds its implied fair value, then an impairment loss equal to the difference would be recorded. We evaluate our finite lived intangible assets for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If any indicator of impairment exists, we assess the recoverability of the affected intangible assets by determining whether the carrying value of the asset can be recovered through undiscounted future operating cash flows. If impairment is indicated, we estimate the asset’s fair value using future discounted cash flows associated with the use of the asset, and adjust the carrying value of the asset accordingly. Recent Accounting Pronouncements With the exception of those discussed below, there have not been any recent changes in accounting pronouncements and Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB) during the three months ended March 31, 2016 that are of significance or potential significance to us. In May 2014, the FASB issued ASU 2014-09 (ASU 2014-09) regarding ASC Topic 606 Revenue from Contracts with Customers. ASU 2014-09 provides principles for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. On July 7, 2015, the FASB amended ASU 2014-09 to defer the effective date by one year with early adoption permitted as of the original effective date. ASU 2014-09 will be effective for our fiscal year beginning January 1, 2018 unless we elect the earlier date of January 1, 2017. We are currently evaluating the accounting, transition, and disclosure requirements of the standard. We have not yet determined whether we will elect early adoption of the standard and cannot currently estimate the financial statement impact of adoption. In July 2015, the FASB issued ASU 2015-11 Inventory (Topic 330): Simplifying the Measurement of Inventory (ASU 2015-11) which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU 2015-11 defines net realizable value as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 will be effective for our fiscal year beginning January 1, 2017. We are currently evaluating the accounting and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption. In November 2015, the FASB issued ASU 2015-17 (ASU 2015-17) ASC 740, Income Taxes, Balance Sheet Classification of Deferred Taxes. The amendments in this update require that in a classified statement of financial position, an entity shall classify deferred tax liabilities and assets as non-current, and an entity shall not offset deferred tax liabilities and assets attributable to different tax-paying components of the entity or to different tax jurisdictions. ASU 2015-17 will be effective for our fiscal year beginning January 1, 2017. We are currently evaluating the accounting and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption. In November 2015, the FASB issued Accounting Standards Update 2015-17 ASC 740, Income Taxes, Balance Sheet Classification of Deferred Taxes, effective for annual periods beginning after December 15, 2016. The amendments in this update require that in a classified statement of financial position, an entity shall classify deferred tax liabilities and assets as non-current, and an entity shall not offset deferred tax liabilities and assets attributable to different tax-paying components of the entity or to different tax jurisdictions. We currently are evaluating the adoption of the provisions of ASU 2015-17 and cannot currently estimate the financial statement impact of adoption. In February 2016, the FASB issued ASU 2016-02 (ASU 2016-02) Leases, requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. Lessor accounting is similar to the current model but updated to align with certain changes to the lessee model. Lessors will continue to classify leases as operating, direct financing or sales-type leases. ASU 2016-02 will be effective for our fiscal year beginning January 1, 2019 and early adoption is permitted. We are currently evaluating the accounting, transition, and disclosure requirements of the standard. We have not yet determined whether we will elect early adoption of the standard and cannot currently estimate the financial statement impact of adoption. In March 2016, the FASB issued ASU 2016-09 (ASU 2016-09) , which simplifies several aspects of the accounting for share-based payments, including changing the threshold to qualify for equity classification up to the employees’ maximum statutory tax rates, allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur, and clarifying the classification on the statement of cash flows employee taxes paid when an employer withholds shares for tax-withholding purposes. ASU 2016-09 will be effective for our fiscal year beginning January 1, 2017. We are currently evaluating the accounting and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption.

Convertible Notes

Convertible Notes	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Convertible Notes	Convertible Notes On February 4, 2014, we closed an underwritten public offering of $201.3 million aggregate principal amount of our 2.75% Senior Convertible Notes due 2034 (Notes) pursuant to an underwriting agreement, dated January 29, 2014. The Notes accrue interest at a rate of 2.75% per year, payable semi-annually in arrears on February 1 and August 1 of each year, commencing August 1, 2014. The Notes will mature on February 1, 2034, unless earlier converted, redeemed, or repurchased in accordance with the terms of the Notes. The initial conversion rate of the Notes is 17.8750 shares of our common stock, par value $0.001 per share, per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $55.94 per share). The conversion rate will be subject to adjustment upon the occurrence of certain specified events. Holders may surrender their Notes for conversion at any time prior to the stated maturity date. On or after February 6, 2018 and prior to February 6, 2021, we may redeem any or all of the Notes in cash if the closing price of our common stock exceeds 130% of the conversion price for a specified number of days, and on or after February 6, 2021, we may redeem any or all of the Notes in cash without any such condition. The redemption price of the Notes will equal 100% of the principal amount of the Notes plus accrued and unpaid interest. Holders may require us to repurchase all or a portion of their Notes on each of February 6, 2021, February 6, 2024, and February 6, 2029 at a repurchase price in cash equal to 100% of the principal amount of the Notes plus accrued and unpaid interest. If we undergo a fundamental change, as defined in the terms of the Notes, holders may require us to repurchase the Notes in whole or in part for cash at a repurchase price equal to 100% of the principal amount of the Notes plus accrued and unpaid interest. In February 2014, we received $195.2 million , net of underwriting discounts, from the issuance of the Notes and incurred approximately $1.1 million in offering-related expenses. The underwriting discount of $6.0 million was recorded as an offset to the proceeds. The balance of unamortized debt discount and debt issuance costs of $6.5 million was included in convertible notes, net as of March 31, 2016 on the accompanying condensed consolidated balance sheet. In February 2014, we used $113.2 million of the net proceeds to fund the cash portion of the consideration payable by us in connection with our acquisition of DVS Sciences, Inc. (now Fluidigm Sciences Inc.) (See Note 4). Interest expense related to the Notes was approximately $1.5 million for the three months ended March 31, 2016 and 2015. Approximately $2.8 million of accrued interest under the Notes became due and was paid during the three months ended March 31, 2016 .

Acquisition

Acquisition	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Acquisition	Acquisition On February 13, 2014 (Acquisition Date), we acquired DVS primarily to broaden our addressable single-cell biology market opportunity and complement our existing product offerings. The contractual price for the acquisition was $207.5 million , subject to certain adjustments as specified in the merger agreement. The measurement period for the acquisition ended on February 12, 2015. The aggregate purchase price was determined to be $199.9 million , as detailed in the table below (in thousands): Estimated Fair Value Cash $ 126,048 Issued 1,759,007 shares of Fluidigm common stock (2) 76,805 Acquisition consideration paid at Acquisition Date 202,853 Accelerated stock compensation (1) (6,690 ) Estimated fair value of vested Fluidigm equivalent stock options (2) 4,039 Working capital adjustment (269 ) Aggregate purchase price $ 199,933 (1) As a part of the acquisition, we accelerated vesting of certain DVS stock options and shares of restricted stock, and incurred a $6.7 million expense, based upon the per share consideration paid to holders of shares of DVS common stock as of February 13, 2014. This expense is accounted for as a separate transaction and reflected in the acquisition-related expenses line of the condensed consolidated statements of operations. (2) In conjunction with the acquisition, we assumed all outstanding DVS stock options and unvested shares of restricted stock and converted, as of the Acquisition Date, the unvested stock options outstanding under the DVS stock option plan into unvested stock options to purchase approximately 143,000 shares of Fluidigm common stock and the unvested DVS restricted stock into approximately 186,000 shares of restricted Fluidigm common stock, retaining the original vesting schedules. The fair value of all converted share-based awards was $14.6 million , of which $4.0 million was attributed to the pre-combination service period and was included in the calculation of the purchase price. The remaining fair value will be recognized over the awards’ remaining vesting periods subsequent to the acquisition. The fair value of the Fluidigm equivalent share-based awards as of the Acquisition Date was estimated using the Black-Scholes valuation model. Approximately 885,000 shares of Fluidigm common stock, with a fair value of $ 38.6 million , representing 50.3030% of the shares otherwise payable to the former stockholders of DVS, were deposited into escrow (Escrowed Shares). The Escrowed Shares comprised a portion of the merger consideration and were being held in escrow to secure indemnification obligations under the merger agreement. Under the terms of the merger agreement, fifty percent ( 50.0% ) of the aggregate shares subject to the indemnification escrow were eligible for release on March 13, 2015 (Initial Release Date), and the balance of the shares were eligible for release on August 13, 2015, provided that in each case shares would have continued to be held in escrow in amounts that we reasonably determined in good faith to be necessary to satisfy any claims for which we had delivered a notice of claim which had not been fully resolved between us and the representative of the former stockholders of DVS (Stockholder Representative). Prior to the Initial Release Date, we submitted escrow claim notices under the terms of the merger agreement. On April 9, 2015, the Stockholder Representative provided notices objecting to our claims. In July 2015, we entered into a settlement agreement with the Stockholder Representative regarding the claims (Settlement Agreement). Pursuant to the terms of the Settlement Agreement, the parties agreed to release approximately 80% of the Escrowed Shares to the former stockholders of DVS, and the remaining approximately 20% of the Escrowed Shares, or 170,107 shares, to us, which were canceled and returned to the status of authorized and unissued shares. Additionally, the parties agreed to, among other things, release various claims and waive certain rights with respect to the merger agreement. On the settlement date, the 170,107 shares had a value of approximately $4.0 million , which was recorded as gain on escrow settlement during the quarter ended September 30, 2015. Net Assets Acquired The transaction has been accounted for using the acquisition method of accounting which requires that assets acquired and liabilities assumed be recognized at their fair values as of the Acquisition Date. The following table summarizes the assets acquired and liabilities assumed as of the Acquisition Date (in thousands): Allocation of purchase price Cash and cash equivalents $ 8,405 Accounts receivable, net 7,698 Inventories 3,489 Prepaid expenses and other current assets 1,482 Property and equipment, net 1,202 Developed technology 112,000 Goodwill 104,108 Other non-current assets 88 Total assets acquired 238,472 Accounts payable (1,114 ) Accrued compensation and related benefits (761 ) Other accrued liabilities (1,204 ) Deferred revenue, current portion (1,844 ) Tax payable (45 ) Deferred tax liability (31,942 ) Deferred revenue, net of current portion (1,629 ) Net assets acquired $ 199,933 The following table provides details of intangible assets acquired in connection with the DVS acquisition as of March 31, 2016 (in thousands, except years): Gross fair value Accumulated Amortization Net Useful Life (years) Developed technology $ 112,000 $ (23,800 ) $ 88,200 10 We recognized $2.8 million in intangible asset amortization expense during the three months ended March 31, 2016 and 2015. Intangible asset amortization expense is recorded in cost of product revenue. The $104.1 million of goodwill recognized as part of the transaction is attributable primarily to expected synergies and other benefits from the acquisition, including expansion of our addressable market from the single-cell genomics market to the larger single-cell biology market and the ability to leverage our larger global commercial sales organization and infrastructure to expand awareness of DVS's products and technology. Goodwill is not deductible for income tax purposes. There were no changes in goodwill between December 31, 2015 and March 31, 2016 .

Balance Sheet Details

Balance Sheet Details	3 Months Ended
	Mar. 31, 2016
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Details	Balance Sheet Details Inventories Inventories consist of the following (in thousands): March 31, 2016 December 31, 2015 Raw materials $ 7,889 $ 6,829 Work-in-process 2,431 2,442 Finished goods 9,250 8,653 Total inventories, net $ 19,570 $ 17,924 Property and Equipment, net Property and equipment, net consisted of the following (in thousands): March 31, 2016 December 31, 2015 Computer equipment and software $ 5,275 $ 5,048 Laboratory and manufacturing equipment 22,270 21,783 Leasehold improvements 6,552 5,875 Office furniture and fixtures 1,634 1,584 35,731 34,290 Less accumulated depreciation and amortization (20,810 ) (19,618 ) Construction-in-progress 449 586 Property and equipment, net $ 15,370 $ 15,258 Intangible Assets The total intangible assets, which include developed technology, net as a result of the DVS acquisition and other intangible assets included in Other non-current assets, was $95.8 million as of March 31, 2016 . The estimated future amortization expense of intangible assets as of March 31, 2016 is as follows (in thousands): Amount 2016 (remainder of the year) $ 9,305 2017 12,391 2018 12,326 2019 12,234 2020 12,234 Thereafter 37,340 $ 95,830

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments As a basis for considering fair value, we follow a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level I: observable inputs such as quoted prices in active markets; Level II: inputs other than quoted prices in active markets that are observable either directly or indirectly; and Level III: unobservable inputs in which there is little or no market data, which requires us to develop our own assumptions. Our cash equivalents, which include money market funds, are classified as Level I because they are valued using quoted market prices. Our investments are generally classified as Level II because their value is based on valuations using significant inputs derived from or corroborated by observable market data. Depending on the security, the income and market approaches are used in the model driven valuations. Inputs of these models include recently executed transaction prices in securities of the issuer or comparable issuers and yield curves. The following table sets forth our financial instruments that were measured at fair value by level within the fair value hierarchy (in thousands): March 31, 2016 December 31, 2015 Level I Level II Level III Total Level I Level II Level III Total Assets Money market funds $ 20,900 $ 20,900 $ 11,228 $ — $ — $ 11,228 U.S. government and agency securities 56,840 56,840 — 72,348 — 72,348 Total assets measured at fair value $ 20,900 $ 56,840 $ — $ 77,740 $ 11,228 $ 72,348 $ — $ 83,576 There were no transfers in and out of Level I and Level II fair value measurement categories during the three months ended March 31, 2016 and 2015, and there were no changes in the valuation techniques used. The following is a summary of investments at March 31, 2016 and December 31, 2015 (in thousands): March 31, 2016 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Estimated Fair Value U.S. government and agency securities $ 52,356 $ 12 $ (3 ) $ 52,365 December 31, 2015 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Estimated Fair Value U.S. government and agency securities $ 72,420 $ — $ (72 ) $ 72,348 The contractual maturity dates of $4.4 million of the U.S. government and agency securities are within 90 days from March 31, 2016. The contractual maturity dates of $52.4 million of our investments are within one year from March 31, 2016 . Based on an evaluation of securities that were in a loss position, we did not recognize any other-than-temporary impairment charges for the three months ended March 31, 2016 and 2015. None of these investments have been in a continuous loss position for more than 12 months. Our conclusion that these losses are not “other-than-temporary” is based on the high credit quality of the securities, their short remaining maturity periods, and our intent and ability to hold such securities until the date of recovery of their respective market values or maturity. The estimated fair value of the Notes is based on a market approach. The estimated fair value was approximately $ 112.7 million (par value $201.3 million ) as of March 31, 2016 and represents a Level II valuation. When determining the estimated fair value of our long-term debt, we used a commonly accepted valuation methodology and market-based risk measurements that are indirectly observable, such as credit risk. The following is a summary of our cash and cash equivalents (in thousands): March 31, 2016 December 31, 2015 Cash $ 17,480 $ 17,889 U.S. government and agency securities 4,474 — Money market funds 20,900 11,228 Cash and cash equivalents $ 42,854 $ 29,117

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases We have entered into various long-term non-cancelable operating leases for equipment and facilities. On April 9, 2013, we entered into an amendment (the April 2013 Amendment) to the lease agreement dated September 14, 2010 (as amended, the Headquarters Lease) relating to the lease of office and laboratory space at our corporate headquarters located in South San Francisco, California. The April 2013 Amendment provided for an expansion of the premises covered under the Headquarters Lease, effective April 1, 2014; an extension of the term to April 30, 2020 with an option to renew for an additional five years; payment of base rent with rent escalation; and payment of certain operating expenses during the term of the Headquarters Lease. The April 2013 Amendment also provided for an allowance of approximately $0.7 million for tenant improvements, of which we used $0.5 million and the remaining $0.2 million was used to offset base rent obligations in the quarter ended September 30, 2015. An additional allowance of approximately $0.5 million for tenant improvements, which, if used, will be repaid in equal monthly payments with interest at a rate of 9% per annum over the remaining term of the Headquarters Lease. The total future minimum lease payments for the additional space, which will be paid through April 2020, are approximately $6.4 million as of March 31, 2016. On June 4, 2014, we entered into an additional amendment to the Headquarters Lease (the June 2014 Amendment), which provided for an expansion of the premises covered under the Headquarters Lease by approximately 13,000 square feet, effective October 1, 2014; payment of base rent with rent escalation; and payment of certain operating expenses during the term of the Headquarters Lease. The June 2014 Amendment also provided for an allowance of approximately $0.2 million for tenant improvements, which was fully utilized by March 31, 2015, and an additional allowance of approximately $0.1 million for tenant improvements, which, if used, will be repaid in equal monthly payments with interest at a rate of 9% per annum over the remaining term of the Headquarters Lease. The total future minimum lease payments for the additional space, which will be paid through April 2020, are approximately $1.9 million as of March 31, 2016 . On September 15, 2014, we entered into an additional amendment to the Headquarters Lease (the September 2014 Amendment), which provided for an expansion of the premises covered under the Headquarters Lease by approximately 9,000 square feet, effective October 1, 2014; payment of base rent with rent escalation; and payment of certain operating expenses during the term of the Headquarters Lease. The September 2014 Amendment also provided for an allowance of approximately $0.2 million for tenant improvements. The total future minimum lease payments for the additional space, which will be paid through April 2020, are approximately $1.3 million as of March 31, 2016 . On December 8, 2015, we entered into an additional amendment to the Headquarters Lease (the December 2015 Amendment), which provides for an expansion of the premises covered under the Headquarters Lease by approximately 24,039 square feet, with a commencement date of April 1, 2016, payment of base rent with rent escalation, and an increase in our share of certain operating expenses during the term of the Headquarters Lease. The December 2015 Amendment also provided for an allowance of up to approximately $0.4 million for tenant improvements. The total future minimum lease payments for the additional space, which will be paid through April 2020, are approximately $3.8 million as of March 31, 2016. On October 14, 2013, Fluidigm Singapore Pte. Ltd., our wholly-owned subsidiary (Fluidigm Singapore) accepted an offer of tenancy (the Singapore Lease) from HSBC Institutional Trust Services (Singapore) Limited, as trustee of Ascendas Real Estate Investment Trust (Landlord), relating to the lease of a new facility located in Singapore. Pursuant to the terms of the Singapore Lease, Fluidigm Singapore took possession of the facility on March 3, 2014 for a term of 99 months, and the Singapore Lease and rental obligations thereunder commenced on June 3, 2014. The Singapore Lease also provides Fluidigm Singapore with an option to renew for an additional 60 months at the then prevailing market rent, and on similar terms as the existing Singapore Lease. In June 2014, Fluidigm Singapore leased additional space of approximately 2,400 square feet in the same building as the new facility on the same terms as the Singapore Lease (the June 2014 Amendment). We completed the consolidation of our Singapore manufacturing operations in the new space in July 2014, and the site qualification was completed in August 2014. In April 2015, Fluidigm Singapore leased additional space of approximately 10,000 square feet in the same building on the same terms as the Singapore Lease (the April 2015 Amendment), and terminated the June 2014 Singapore Amendment as of June 30, 2015. The total future minimum lease payments for the facility, which will be paid through June 2022, are approximately $4.2 million as of March 31, 2016. On August 18, 2015, we, Fluidigm Canada Inc., our wholly-owned subsidiary (Fluidigm Canada), and Rodick Equities, Inc. entered into a lease dated as of August 17, 2015 (the New Canada Lease), relating to the lease of approximately 41,145 square feet of office, laboratory, and warehouse space at a facility in Markham, Ontario, Canada. Pursuant to the terms of the New Canada Lease, Fluidigm Canada was in possession of the new space commencing on or about August 27, 2015, and rental obligations thereunder commenced on April 1, 2016 for a term of 10 years. The New Canada Lease provides for an allowance for tenant improvements, an option to renew the Lease for an additional five years, and a right of first offer on certain additional space in the Building. In connection with our acquisition of DVS, we acquired the operating leases for facilities in Sunnyvale, California and Markham, Ontario, Canada. (See Note 4 to our condensed consolidated financial statements for additional information). The Sunnyvale lease will terminate in July 2016. The Markham lease terminated on April 30, 2016. The total future minimum payments under the Sunnyvale and Markham leases were approximately $76,000 as of March 31, 2016. In March 2016, the Company and ARE-NC Region No. 5, LLC, a Delaware limited liability company, entered into a lease (the North Carolina Lease), relating to the lease of approximately 12,824 square feet of office, laboratory, and manufacturing space at a facility in Durham, North Carolina. Pursuant to the terms of the North Carolina Lease, we took possession of the facility commencing in March 2016, and rental obligations thereunder will commence in September 2016, for a term of 60 months from October 1, 2016. The North Carolina Lease provides for an allowance for tenant improvements, an option for an additional tenant improvement allowance with additional rent payments above the minimum lease payments, and two options to renew the Lease for an additional three years each. The total future minimum lease payments for the facility, which will be paid through September 30, 2021, are approximately $1.4 million as of March 31, 2016. We have entered into several license and patent agreements. Under these agreements, we pay annual license maintenance fees, nonrefundable license issuance fees, and royalties as a percentage of net sales for the sale or sublicense of products using the licensed technology. Future payments related to these license agreements have not been included in the contractual obligations table above as the period of time over which the future license payments will be required to be made, and the amount of such payments, are indeterminable. We do not expect the license payments to be material in any particular year. Warranty We accrue for estimated warranty obligations at the time of product shipment. Management periodically reviews the estimated fair value of its warranty liability and records adjustments based on the terms of warranties provided to customers, historical and anticipated warranty claim experience. Activity for our warranty accrual for the three months ended March 31, 2016 and 2015, which is included in other accrued liabilities, is summarized below (in thousands): Three Months Ended 2016 2015 Beginning balance $ 1,076 $ 1,178 Warranty accrual (charges), net (20 ) (114 ) Ending balance $ 1,056 $ 1,064 Indemnifications From time to time, we have entered into indemnification provisions under certain of our agreements in the ordinary course of business, typically with business partners, customers, and suppliers. Pursuant to these agreements, we may indemnify, hold harmless, and agree to reimburse the indemnified parties on a case-by-case basis for losses suffered or incurred by the indemnified parties in connection with any patent or other intellectual property infringement claim by any third party with respect to our products. The term of these indemnification provisions is generally perpetual from the time of the execution of the agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is typically not limited to a specific amount. In addition, we have entered into indemnification agreements with our officers, directors, and certain other employees. With certain exceptions, these agreements provide for indemnification for related expenses including, among others, attorneys' fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As of March 31, 2016, we had no accrued liabilities for these indemnification provisions. Contingencies From time to time, we may be subject to various legal proceedings and claims arising in the ordinary course of business. We assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation During the three months ended March 31, 2016 and 2015, we granted certain employees options to purchase 520,000 and 276,000 shares of common stock, respectively. The options granted during the three months ended March 31, 2016 had exercise prices ranging from $5.78 to $7.44 and a total grant date fair value of $3.7 million . The options granted during the three months ended March 31, 2015 had exercise prices ranging from $38.53 to $44.20 and a total grant date fair value of $5.5 million . During the three months ended March 31, 2016 and 2015, we granted certain employees 679,000 and 349,000 restricted stock units, respectively. The restricted stock units granted during the three months ended March 31, 2016 had fair market values ranging from $5.70 to $7.44 and a total grant date fair value of $4.8 million . The restricted stock units granted during the three months ended March 31, 2015 had fair markets values ranging from $37.45 to $44.20 and a total grant date fair value of $14.3 million . The expenses relating to these options and restricted stock units will be recognized over their respective four -year vesting periods. We recognized stock-based compensation expense of $3.7 million and $4.1 million during the three months ended March 31, 2016 and 2015, respectively. As of March 31, 2016 , we had $10.7 million and $20.2 million of unrecognized stock-based compensation costs related to stock options and restricted stock units, respectively, which are expected to be recognized over a weighted average period of 2.3 years and 2.9 years, respectively. In conjunction with the DVS acquisition, we assumed all outstanding DVS stock options and unvested shares of restricted stock (See Note 4). As of March 31, 2016 , we had $0.2 million of unrecognized stock-based compensation costs related to the assumed stock options, which are expected to be recognized over a remaining weighted average period of 1.1 years.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The provision or benefit for income taxes for the periods presented differs from the 34% U.S. Federal statutory rate primarily due to maintaining a valuation allowance for U.S. losses and tax assets, which we do not consider to be realizable. We recorded a tax benefit of $0.8 million and $0.6 million for the three months ended March 31, 2016 and 2015, which was primarily attributable to the amortization of our acquisition-related deferred tax liability, partially offset by tax provision and provision for uncertain tax liabilities related to our foreign operations.

Information about Geographic Ar

Information about Geographic Areas	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Information about Geographic Areas	Information about Geographic Areas We operate in one reporting segment, which is the development, manufacturing, and commercialization of life science analytical and preparatory systems consisting of instruments and consumables for academic institutions, clinical laboratories, biopharmaceutical, Ag-Bio companies and contract research organizations in growth markets, such as single-cell biology and production genomics. The following table presents our total revenue by geography of our customers for each period presented (in thousands): Three Months Ended March 31, 2016 2015 United States $ 13,174 $ 13,794 Europe 9,325 6,916 Asia-Pacific 6,008 5,205 Other 496 814 Total $ 29,003 $ 26,729 No individual customer represented more than 10% of our revenues for the three months ended March 31, 2016 and 2015. China represents 11% or $3.3 million and 6% or $1.5 million for the three months ended March 31, 2016 and 2015, respectively.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2015 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. These financial statements have been prepared on the same basis as our annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair statement of our financial information. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016 or for any other interim period or for any other future year. All intercompany accounts and transactions have been eliminated upon consolidation. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, income tax provisions, stock-based compensation, inventory valuation, allowances for doubtful accounts, and useful lives of long-lived assets. We base our estimates on historical experience and on various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates.
Net Loss per Share	Net Loss per Share Our basic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Restricted stock units and options to purchase common stock are considered to be potentially dilutive common shares but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented.
Business Combinations	Business Combinations Assets acquired and liabilities assumed as part of a business acquisition are generally recorded at their fair value at the date of acquisition. The excess of purchase price over the fair value of assets acquired and liabilities assumed is recorded as goodwill. Determining fair value of identifiable assets, particularly intangibles, and liabilities acquired also requires management to make estimates, which are based on all available information, and in some cases, assumptions with respect to the timing and amount of future revenues and expenses associated with an asset. Accounting for business acquisitions requires management to make judgments as to whether a purchase transaction is a multiple element contract, meaning that it includes other transaction components such as a settlement of a preexisting relationship. This judgment and determination affects the amount of consideration paid that is allocable to assets and liabilities acquired in the business purchase transaction (See Note 4).
Long-lived Assets, including Goodwill	Long-lived Assets, including Goodwill Goodwill and intangible assets with indefinite lives are not subject to amortization, but are tested for impairment on an annual basis during the fourth quarter or whenever events or changes in circumstances indicate the carrying amount of these assets may not be recoverable. We first conduct an assessment of qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we determine that it is more likely than not that the fair value of our reporting unit is less than its carrying amount, we then conduct a two-step test for impairment of goodwill. In the first step, we compare the fair value of our reporting unit to its carrying value. If the fair value of our reporting unit exceeds its carrying value, goodwill is not considered impaired and no further analysis is required. If the carrying value of the reporting unit exceeds its fair value, then the second step of the impairment test must be performed in order to determine the implied fair value of the goodwill. If the carrying value of the goodwill exceeds its implied fair value, then an impairment loss equal to the difference would be recorded. We evaluate our finite lived intangible assets for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If any indicator of impairment exists, we assess the recoverability of the affected intangible assets by determining whether the carrying value of the asset can be recovered through undiscounted future operating cash flows. If impairment is indicated, we estimate the asset’s fair value using future discounted cash flows associated with the use of the asset, and adjust the carrying value of the asset accordingly.
Recent Accounting Pronouncements	Recent Accounting Pronouncements With the exception of those discussed below, there have not been any recent changes in accounting pronouncements and Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB) during the three months ended March 31, 2016 that are of significance or potential significance to us. In May 2014, the FASB issued ASU 2014-09 (ASU 2014-09) regarding ASC Topic 606 Revenue from Contracts with Customers. ASU 2014-09 provides principles for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. On July 7, 2015, the FASB amended ASU 2014-09 to defer the effective date by one year with early adoption permitted as of the original effective date. ASU 2014-09 will be effective for our fiscal year beginning January 1, 2018 unless we elect the earlier date of January 1, 2017. We are currently evaluating the accounting, transition, and disclosure requirements of the standard. We have not yet determined whether we will elect early adoption of the standard and cannot currently estimate the financial statement impact of adoption. In July 2015, the FASB issued ASU 2015-11 Inventory (Topic 330): Simplifying the Measurement of Inventory (ASU 2015-11) which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU 2015-11 defines net realizable value as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 will be effective for our fiscal year beginning January 1, 2017. We are currently evaluating the accounting and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption. In November 2015, the FASB issued ASU 2015-17 (ASU 2015-17) ASC 740, Income Taxes, Balance Sheet Classification of Deferred Taxes. The amendments in this update require that in a classified statement of financial position, an entity shall classify deferred tax liabilities and assets as non-current, and an entity shall not offset deferred tax liabilities and assets attributable to different tax-paying components of the entity or to different tax jurisdictions. ASU 2015-17 will be effective for our fiscal year beginning January 1, 2017. We are currently evaluating the accounting and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption. In November 2015, the FASB issued Accounting Standards Update 2015-17 ASC 740, Income Taxes, Balance Sheet Classification of Deferred Taxes, effective for annual periods beginning after December 15, 2016. The amendments in this update require that in a classified statement of financial position, an entity shall classify deferred tax liabilities and assets as non-current, and an entity shall not offset deferred tax liabilities and assets attributable to different tax-paying components of the entity or to different tax jurisdictions. We currently are evaluating the adoption of the provisions of ASU 2015-17 and cannot currently estimate the financial statement impact of adoption. In February 2016, the FASB issued ASU 2016-02 (ASU 2016-02) Leases, requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. Lessor accounting is similar to the current model but updated to align with certain changes to the lessee model. Lessors will continue to classify leases as operating, direct financing or sales-type leases. ASU 2016-02 will be effective for our fiscal year beginning January 1, 2019 and early adoption is permitted. We are currently evaluating the accounting, transition, and disclosure requirements of the standard. We have not yet determined whether we will elect early adoption of the standard and cannot currently estimate the financial statement impact of adoption. In March 2016, the FASB issued ASU 2016-09 (ASU 2016-09) , which simplifies several aspects of the accounting for share-based payments, including changing the threshold to qualify for equity classification up to the employees’ maximum statutory tax rates, allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur, and clarifying the classification on the statement of cash flows employee taxes paid when an employer withholds shares for tax-withholding purposes. ASU 2016-09 will be effective for our fiscal year beginning January 1, 2017. We are currently evaluating the accounting and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption.
Fair Value of Financial Instruments	Fair Value of Financial Instruments As a basis for considering fair value, we follow a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level I: observable inputs such as quoted prices in active markets; Level II: inputs other than quoted prices in active markets that are observable either directly or indirectly; and Level III: unobservable inputs in which there is little or no market data, which requires us to develop our own assumptions. Our cash equivalents, which include money market funds, are classified as Level I because they are valued using quoted market prices. Our investments are generally classified as Level II because their value is based on valuations using significant inputs derived from or corroborated by observable market data. Depending on the security, the income and market approaches are used in the model driven valuations. Inputs of these models include recently executed transaction prices in securities of the issuer or comparable issuers and yield curves.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Summary of potential common shares excluded from computations of diluted net loss per share attributed to common stockholders	The following potentially dilutive common shares were excluded from the computation of diluted net loss per share for the interim periods presented because they would have been anti-dilutive (in thousands): Three Months Ended March 31, 2016 2015 Stock options, restricted stock units and restricted stock awards 4,911 3,940 Convertible notes 3,598 3,598 Total 8,509 7,538
Summary of comprehensive loss	The components of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2016 are summarized as follows (in thousands): Net Unrealized Gain (Loss) on Marketable Securities Foreign Currency Translation Adjustment Accumulated Other Comprehensive Loss Balance at December 31, 2015 $ (72 ) $ (1,072 ) $ (1,144 ) Other comprehensive income 81 178 259 Balance at March 31, 2016 $ 9 $ (894 ) $ (885 )

Acquisition (Tables)

Acquisition (Tables)	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Schedule of consideration transferred	The aggregate purchase price was determined to be $199.9 million , as detailed in the table below (in thousands): Estimated Fair Value Cash $ 126,048 Issued 1,759,007 shares of Fluidigm common stock (2) 76,805 Acquisition consideration paid at Acquisition Date 202,853 Accelerated stock compensation (1) (6,690 ) Estimated fair value of vested Fluidigm equivalent stock options (2) 4,039 Working capital adjustment (269 ) Aggregate purchase price $ 199,933 (1) As a part of the acquisition, we accelerated vesting of certain DVS stock options and shares of restricted stock, and incurred a $6.7 million expense, based upon the per share consideration paid to holders of shares of DVS common stock as of February 13, 2014. This expense is accounted for as a separate transaction and reflected in the acquisition-related expenses line of the condensed consolidated statements of operations. (2) In conjunction with the acquisition, we assumed all outstanding DVS stock options and unvested shares of restricted stock and converted, as of the Acquisition Date, the unvested stock options outstanding under the DVS stock option plan into unvested stock options to purchase approximately 143,000 shares of Fluidigm common stock and the unvested DVS restricted stock into approximately 186,000 shares of restricted Fluidigm common stock, retaining the original vesting schedules. The fair value of all converted share-based awards was $14.6 million , of which $4.0 million was attributed to the pre-combination service period and was included in the calculation of the purchase price. The remaining fair value will be recognized over the awards’ remaining vesting periods subsequent to the acquisition. The fair value of the Fluidigm equivalent share-based awards as of the Acquisition Date was estimated using the Black-Scholes valuation model.
Schedule of consideration transferred and assets acquired and liabilities assumed	The following table summarizes the assets acquired and liabilities assumed as of the Acquisition Date (in thousands): Allocation of purchase price Cash and cash equivalents $ 8,405 Accounts receivable, net 7,698 Inventories 3,489 Prepaid expenses and other current assets 1,482 Property and equipment, net 1,202 Developed technology 112,000 Goodwill 104,108 Other non-current assets 88 Total assets acquired 238,472 Accounts payable (1,114 ) Accrued compensation and related benefits (761 ) Other accrued liabilities (1,204 ) Deferred revenue, current portion (1,844 ) Tax payable (45 ) Deferred tax liability (31,942 ) Deferred revenue, net of current portion (1,629 ) Net assets acquired $ 199,933
Fair value estimate of identifiable intangibles assets acquired	The following table provides details of intangible assets acquired in connection with the DVS acquisition as of March 31, 2016 (in thousands, except years): Gross fair value Accumulated Amortization Net Useful Life (years) Developed technology $ 112,000 $ (23,800 ) $ 88,200 10

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	3 Months Ended
	Mar. 31, 2016
Balance Sheet Related Disclosures [Abstract]
Inventories	Inventories consist of the following (in thousands): March 31, 2016 December 31, 2015 Raw materials $ 7,889 $ 6,829 Work-in-process 2,431 2,442 Finished goods 9,250 8,653 Total inventories, net $ 19,570 $ 17,924
Property, plant and equipment, net	Property and equipment, net consisted of the following (in thousands): March 31, 2016 December 31, 2015 Computer equipment and software $ 5,275 $ 5,048 Laboratory and manufacturing equipment 22,270 21,783 Leasehold improvements 6,552 5,875 Office furniture and fixtures 1,634 1,584 35,731 34,290 Less accumulated depreciation and amortization (20,810 ) (19,618 ) Construction-in-progress 449 586 Property and equipment, net $ 15,370 $ 15,258
Schedule of future amortization expense of intangible assets	The estimated future amortization expense of intangible assets as of March 31, 2016 is as follows (in thousands): Amount 2016 (remainder of the year) $ 9,305 2017 12,391 2018 12,326 2019 12,234 2020 12,234 Thereafter 37,340 $ 95,830

Fair Value of Financial Instr21

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Financial instruments measured at fair value by level within the fair value hierarchy	The following table sets forth our financial instruments that were measured at fair value by level within the fair value hierarchy (in thousands): March 31, 2016 December 31, 2015 Level I Level II Level III Total Level I Level II Level III Total Assets Money market funds $ 20,900 $ 20,900 $ 11,228 $ — $ — $ 11,228 U.S. government and agency securities 56,840 56,840 — 72,348 — 72,348 Total assets measured at fair value $ 20,900 $ 56,840 $ — $ 77,740 $ 11,228 $ 72,348 $ — $ 83,576
Summary of investments	The following is a summary of investments at March 31, 2016 and December 31, 2015 (in thousands): March 31, 2016 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Estimated Fair Value U.S. government and agency securities $ 52,356 $ 12 $ (3 ) $ 52,365 December 31, 2015 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Estimated Fair Value U.S. government and agency securities $ 72,420 $ — $ (72 ) $ 72,348
Summary of cash and cash equivalents	The following is a summary of our cash and cash equivalents (in thousands): March 31, 2016 December 31, 2015 Cash $ 17,480 $ 17,889 U.S. government and agency securities 4,474 — Money market funds 20,900 11,228 Cash and cash equivalents $ 42,854 $ 29,117

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of warranty accrual	Activity for our warranty accrual for the three months ended March 31, 2016 and 2015, which is included in other accrued liabilities, is summarized below (in thousands): Three Months Ended 2016 2015 Beginning balance $ 1,076 $ 1,178 Warranty accrual (charges), net (20 ) (114 ) Ending balance $ 1,056 $ 1,064

Information about Geographic 23

Information about Geographic Areas (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Product revenue by geography based on billing address of customers	The following table presents our total revenue by geography of our customers for each period presented (in thousands): Three Months Ended March 31, 2016 2015 United States $ 13,174 $ 13,794 Europe 9,325 6,916 Asia-Pacific 6,008 5,205 Other 496 814 Total $ 29,003 $ 26,729

Description of Business (Detail

Description of Business (Details)	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Incorporation of the company	May 11, 1999
Reincorporation of the company	2007-07

Summary of Significant Accoun25

Summary of Significant Accounting Policies - Potential Common Shares Excluded from Computations of Diluted Net Loss Per Share Attributed to Common Stockholders (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive common shares excluded from the computation of diluted net loss per share (shares)	8,509	7,538
Stock options, restricted stock units and restricted stock awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive common shares excluded from the computation of diluted net loss per share (shares)	4,911	3,940
Convertible notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive common shares excluded from the computation of diluted net loss per share (shares)	3,598	3,598

Summary of Significant Accoun26

Summary of Significant Accounting Policies - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance at beginning period	$ (1,144)
Other comprehensive (loss) income	259	$ 194
Balance at period end	(885)
Net Unrealized Gain (Loss) on Marketable Securities
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance at beginning period	(72)
Other comprehensive (loss) income	81
Balance at period end	9
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance at beginning period	(1,072)
Other comprehensive (loss) income	178
Balance at period end	(894)
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance at beginning period	(1,144)
Other comprehensive (loss) income	259
Balance at period end	$ (885)

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended
	Jan. 31, 2016	Mar. 31, 2013	Feb. 28, 2013	Mar. 31, 2016	Mar. 31, 2015	Sep. 30, 2014	Dec. 31, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Proceeds from sale of investment in Verinata				$ 2,330	$ 0
Verinata | Cost-method Investments
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Aggregate disposal value			$ 350,000
Contingent milestone payment receivable for shareholders in cost method investment			100,000
Proceeds from sale of investment in Verinata		$ 3,100
Gain on sale of cost method investment		$ 1,800				$ 300
Long-term Debt | Accounting Standards Update 2015-03
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Unamortized debt issuance expense				1,000			$ 1,000
Other Noncurrent Assets | Accounting Standards Update 2015-03
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Unamortized debt issuance expense				$ (1,000)			$ (1,000)
Other Assets | Verinata | Cost-method Investments
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Contingent milestone payment receivable for shareholders in cost method investment			$ 2,300
Proceeds from contingent milestone payments	$ 2,300

Convertible Notes (Details)

Convertible Notes (Details) - USD ($)	Feb. 04, 2014	Feb. 28, 2014	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)	$ 0.001		$ 0.001		$ 0.001
Interest expense			$ 1,453,000	$ 1,453,000
Convertible Debt | Senior Convertible Notes due 2034
Debt Instrument [Line Items]
Face amount of Notes	$ 201,300,000
Interest rate on Notes (percent)	2.75%
Initial conversion rate of Notes	17.8750
Principal amount of notes	$ 1,000
Initial conversion price of stock	$ 55.94
Debt instrument redemption price when undergo fundamental change (in percent)	100.00%
Proceeds from issuance of convertible notes, net		$ 195,200,000
Debt offering-related expenses		1,100,000
Underwriting discount		6,000,000
Unamortized debt discount and debt issuance costs			6,500,000
Interest expense			1,500,000
Interest paid			$ 2,800,000
February 6, 2018 - February 6, 2021 | Convertible Debt | Senior Convertible Notes due 2034
Debt Instrument [Line Items]
Debt redemption conditioned upon common stock value exceeding a percentage of the conversion price (in percent)	130.00%
On or after February 6, 2021 | Convertible Debt | Senior Convertible Notes due 2034
Debt Instrument [Line Items]
Debt instrument redemption price (in percent)	100.00%
February 5, 2021, February 6, 2024, and February 6, 2029 | Convertible Debt | Senior Convertible Notes due 2034
Debt Instrument [Line Items]
Debt instrument redemption price (in percent)	100.00%
DVS Sciences, Inc.
Debt Instrument [Line Items]
Cash payment in a business combination, Gross		$ 113,200,000

Acquisition (Details)

Acquisition (Details) - USD ($) $ in Thousands	Jul. 01, 2015	Feb. 13, 2014	Mar. 31, 2016	Dec. 31, 2015	Jul. 31, 2015
Business Acquisition [Line Items]
Goodwill			$ 104,108	$ 104,108
DVS Sciences, Inc.
Business Acquisition [Line Items]
Contractual price for the acquisition		$ 207,500
Estimated purchase price consideration		$ 199,933
Number of shares deposited into escrow to secure indemnification obligations (in shares)		885,000
Fair value of shares deposited into escrow to secure indemnification obligations		$ 38,600
Percentage of shares issued in a business combination deposited in escrow to secure indemnification obligations		50.303%
Percentage of secured indemnification to be released		50.00%
Percentage of Escrowed Shares to be released to former DVS stockholders					80.00%
Percent of Escrowed Shares to be released to Fluidigm					20.00%
Escrowed shares released to Fluidigm	170,107
Gain on escrow settlement	$ 4,000
Goodwill		$ 104,108
Acquisition related costs			$ 0

Acquisition - Schedule of Consi

Acquisition - Schedule of Consideration Transferred and Identifiable Assets and Liabilities (Details) - USD ($) $ in Thousands		Feb. 13, 2014	Mar. 31, 2016	Dec. 31, 2015
Recognized Assets [Abstract]
Goodwill			$ 104,108	$ 104,108
DVS Sciences, Inc.
Business Combination, Consideration Transferred [Abstract]
Cash		$ 126,048
Issued 1,759,007 shares of Fluidigm common stock		76,805
Acquisition consideration paid at Acquisition Date		202,853
Accelerated stock compensation	[1]	(6,690)
Estimated fair value of vested Fluidigm equivalent stock options	[2]	4,039
Working capital adjustment		(269)
Aggregate purchase price		$ 199,933
Number of shares issued in business combination (in shares)		1,759,007
Recognized Assets [Abstract]
Cash and cash equivalents		$ 8,405
Accounts receivable, net		7,698
Inventories		3,489
Prepaid expenses and other current assets		1,482
Property and equipment, net		1,202
Developed technology		112,000
Goodwill		104,108
Other non-current assets		88
Total assets acquired		238,472
Recognized Liabilities [Abstract]
Accounts payable		(1,114)
Accrued compensation and related benefits		(761)
Other accrued liabilities		(1,204)
Deferred revenue, current portion		(1,844)
Tax payable		(45)
Deferred tax liability		(31,942)
Deferred revenue, net of current portion		(1,629)
Net assets acquired		199,933
Acquisition-related expenses			$ 0
Stock Options | DVS Sciences, Inc.
Business Combination, Consideration Transferred [Abstract]
Estimated fair value of vested Fluidigm equivalent stock options		$ 4,000
Option to purchase shares of Fluidigm common stock in an acquisition (in shares)		143,000
Option to purchase shares of Fluidigm common stock		$ 14,600
Restricted Stock | DVS Sciences, Inc.
Business Combination, Consideration Transferred [Abstract]
Option to purchase shares of Fluidigm common stock in an acquisition (in shares)		186,000
[1]	As a part of the acquisition, we accelerated vesting of certain DVS stock options and shares of restricted stock, and incurred a $6.7 million expense, based upon the per share consideration paid to holders of shares of DVS common stock as of February 13, 2014. This expense is accounted for as a separate transaction and reflected in the acquisition-related expenses line of the condensed consolidated statements of operations.
[2]	In conjunction with the acquisition, we assumed all outstanding DVS stock options and unvested shares of restricted stock and converted, as of the Acquisition Date, the unvested stock options outstanding under the DVS stock option planinto unvested stock options to purchase approximately 143,000 shares of Fluidigm common stock and the unvested DVS restricted stock into approximately 186,000 shares of restricted Fluidigm common stock, retaining the original vesting schedules. The fair value of all converted share-based awards was $14.6 million, of which $4.0 million was attributed to the pre-combination service period and was included in the calculation of the purchase price. The remaining fair value will be recognized over the awards’ remaining vesting periods subsequent to the acquisition. The fair value of the Fluidigm equivalent share-based awards as of the Acquisition Date was estimated using the Black-Scholes valuation model.

Acquisition - Acquired Intangib

Acquisition - Acquired Intangible Assets (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Net	$ 95,830
Developed Technology Rights
Business Acquisition [Line Items]
Estimated fair value of intangible assets acquired	2,800
Developed Technology Rights | DVS Sciences, Inc.
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Gross	112,000
Accumulated Amortization	(23,800)
Finite-Lived Intangible Assets, Net	$ 88,200
Useful Life	10 years

Balance Sheet Details - Invent

Balance Sheet Details - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 7,889	$ 6,829
Work-in-process	2,431	2,442
Finished goods	9,250	8,653
Inventories	$ 19,570	$ 17,924

Balance Sheet Details - Proper

Balance Sheet Details - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, excluding construction in process, gross	$ 35,731	$ 34,290
Less accumulated depreciation and amortization	(20,810)	(19,618)
Construction-in-progress	449	586
Property and equipment, net	15,370	15,258
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	5,275	5,048
Laboratory and manufacturing equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	22,270	21,783
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	6,552	5,875
Office furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,634	$ 1,584

Balance Sheet Details - Intang

Balance Sheet Details - Intangible Assets (Details) $ in Thousands	Mar. 31, 2016USD ($)
Balance Sheet Related Disclosures [Abstract]
2016 (remainder of the year)	$ 9,305
2,017	12,391
2,018	12,326
2,019	12,234
2,020	12,234
Thereafter	37,340
Finite-Lived Intangible Assets, Net	$ 95,830

Fair Value of Financial Instr35

Fair Value of Financial Instruments - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	$ 77,740	$ 83,576
Money market funds
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	20,900	11,228
U.S. government and agency securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	56,840	72,348
Level I
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	20,900	11,228
Level I | Money market funds
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	20,900	11,228
Level I | U.S. government and agency securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value		0
Level II
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	56,840	72,348
Level II | Money market funds
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value		0
Level II | U.S. government and agency securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	56,840	72,348
Level III
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	$ 0	0
Level III | Money market funds
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value		0
Level III | U.S. government and agency securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value		$ 0

Fair Value of Financial Instr36

Fair Value of Financial Instruments - Summary of Investments and Cash Equivalents (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
U.S. government and agency securities maturing within one year	$ 52,400
U.S. government and agency securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	52,356	$ 72,420
Gross Unrealized Gain	12	0
Gross Unrealized Loss	(3)	(72)
Estimated Fair Value	52,365	$ 72,348
U.S. government and agency securities maturing within one year	$ 4,400

Fair Value of Financial Instr37

Fair Value of Financial Instruments - Summary of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Cash	$ 17,480	$ 17,889
U.S. government and agency securities	4,474	0
Money market funds	20,900	11,228
Cash and cash equivalents	$ 42,854	$ 29,117	$ 36,982	$ 33,713

Fair Value of Financial Instr38

Fair Value of Financial Instruments (Details) $ in Millions	Mar. 31, 2016USD ($)Investment
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contractual maturity	$ 52.4
Number of investments have been in a continuous loss position for more than 12 months | Investment	0
Level II | Estimate of Fair Value Measurement
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value disclosure of Notes	$ 112.7
Level II | Reported Value Measurement
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value disclosure of Notes	201.3
U.S. government and agency securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contractual maturity	$ 4.4

Commitments and Contingencies39

Commitments and Contingencies (Details) $ in Thousands	Dec. 08, 2015USD ($)ft²	Aug. 18, 2015ft²	Sep. 15, 2014USD ($)ft²	Jun. 04, 2014USD ($)ft²	Oct. 14, 2013	Apr. 09, 2013USD ($)	Mar. 31, 2016USD ($)ft²renewal_option	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Apr. 30, 2015ft²	Jun. 30, 2014ft²
Operating Lease, Amendment 2013
Commitments And Contingencies Disclosure [Line Items]
Lease expiration date						Apr. 30, 2020
Operating lease renewal term						5 years
Allowance for tenant improvements						$ 700
Tenant Improvements									$ 500
Base rent obligations								$ 200
Additional tenant improvement allowance						$ 500
Effective interest rate of facility leases						9.00%
Total minimum payments							$ 6,400
June 2014 Amendment
Commitments And Contingencies Disclosure [Line Items]
Allowance for tenant improvements				$ 200
Additional tenant improvement allowance				$ 100
Effective interest rate of facility leases				9.00%
Area of office space for expansion | ft²				13,000
Total minimum payments							1,900
September 2014 Amendment
Commitments And Contingencies Disclosure [Line Items]
Allowance for tenant improvements			$ 200
Area of office space for expansion | ft²			9,000
Total minimum payments							1,300
December 2015 Amendment
Commitments And Contingencies Disclosure [Line Items]
Allowance for tenant improvements	$ 400
Area of office space for expansion | ft²	24,039
Total minimum payments							3,800
Singapore Operating Lease, June 2014 | SINGAPORE
Commitments And Contingencies Disclosure [Line Items]
Operating lease renewal term					60 months
Area of office space for expansion | ft²											2,400
Operating leases, term of contract					99 months
Singapore Operating Lease, April 2015 | SINGAPORE
Commitments And Contingencies Disclosure [Line Items]
Area of office space for expansion | ft²										10,000
Total minimum payments							4,200
Operating Lease, Sunnyvale and Markham
Commitments And Contingencies Disclosure [Line Items]
Total minimum payments							$ 76
New Canada Lease, August 2015
Commitments And Contingencies Disclosure [Line Items]
Operating lease renewal term		5 years
Area of real estate property | ft²		41,145
Operating leases, term of contract		10 years
North Carolina Lease, March 2016
Commitments And Contingencies Disclosure [Line Items]
Operating lease renewal term							3 years
Total minimum payments							$ 1,400
Area of real estate property | ft²							12,824
Operating leases, term of contract							60 months
Number of renewal options | renewal_option							2

Commitments and Contingencies -

Commitments and Contingencies - Warranty Accrual (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Movement in Standard Product Warranty Accrual [Roll Forward]
Beginning balance	$ 1,076	$ 1,178
Warranty accrual (charges), net	(20)	(114)
Ending balance	$ 1,056	$ 1,064

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Stock-based compensation
Stock-based compensation expense	$ 3.7	$ 4.1
Stock Options
Stock-based compensation
Employee stock options granted	520	276
Total grant date fair value	$ 3.7	$ 5.5
Total unrecognized compensation cost related to stock-based compensation arrangements	$ 10.7
Unrecognized compensation cost related to stock-based compensation arrangements average recognition period	2 years 3 months
Stock Options | Minimum
Stock-based compensation
Exercise price of options granted	$ 5.78	$ 38.53
Stock Options | Maximum
Stock-based compensation
Exercise price of options granted	$ 7.44	$ 44.20
Restricted Stock Units (RSUs)
Stock-based compensation
Total grant date fair value	$ 4.8	$ 14.3
Number of stock units granted	679	349
Vesting period of the grant date fair value	4 years
Total unrecognized compensation cost related to stock-based compensation arrangements	$ 20.2
Unrecognized compensation cost related to stock-based compensation arrangements average recognition period	2 years 11 months
Restricted Stock Units (RSUs) | Minimum
Stock-based compensation
Weighted average fair value per stock units granted	$ 5.70	$ 37.45
Restricted Stock Units (RSUs) | Maximum
Stock-based compensation
Weighted average fair value per stock units granted	$ 7.44	$ 44.20
DVS Sciences, Inc. | Stock Options
Stock-based compensation
Total unrecognized compensation cost related to stock-based compensation arrangements	$ 0.2
Unrecognized compensation cost related to stock-based compensation arrangements average recognition period	1 year 1 month

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Tax provision or benefit at federal statutory rate	34.00%
Benefit from income taxes	$ 762	$ 643

Information about Geographic 43

Information about Geographic Areas (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)Segment	Mar. 31, 2015USD ($)
Concentration Risk [Line Items]
Number of reporting segment | Segment	1
Revenues	$ 29,003	$ 26,729
Revenue | China
Concentration Risk [Line Items]
Concentration risk percent	11.00%	6.00%
Revenues	$ 3,300	$ 1,500

Information about Geographic 44

Information about Geographic Areas - Product Revenue by Geography (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Total product revenue
Total	$ 29,003	$ 26,729
United States
Total product revenue
Total	13,174	13,794
Europe
Total product revenue
Total	9,325	6,916
Asia-Pacific
Total product revenue
Total	6,008	5,205
Other
Total product revenue
Total	$ 496	$ 814